Insulin-Like Growth Factor 1 Receptor Expression for Predicting PD-1/PD-L1 Inhibitor Response in Hypopharyngeal Squamous Cell CarcinomaOA
Objectives:Insulin-like growth factor 1 receptor(IGF-1R)is crucial for immunological control and the development of different types of cancer.It is still uncertain how the expression of IGF-1R impacts hypopharyngeal squamous cell carcinoma(HPSCC)and whether it has any predictive value for prognosis.Therefore,this study aimed to investigate the prognostic value of IGF-1R in HPSCC and its connection to tumor immunity.Methods:Correlation between IGF-1R,p16,and tumor-infiltrating immune cells from the TCGA HNSCC data set was analyzed.The expressions of IGF-1R and programmed death ligand(PD-L1)and immune cell density were analyzed using immunohistochemistry(IHC)and multiplex immunohistochemistry(mIHC)in p16+/p16-HPSCC.Overall,114 surgical specimens from 51 p16+patients and 63 p16-patients with a bioptic diagnosis of HPSCC who underwent surgical resection at the Second Affiliated Hospital of Harbin Medical University were analyzed.Results:IGF-1R and PD-L1 were expressed in tumor cells and invasion-front immune cells.Expression of IGF-1R and PD-L1 was related to tumor grade and lymph node status.In patients with p16-HPSCC,IGF-1R and PD-L1 expression were significantly higher than those with p16+HPSCC,as were CD68+or CD163+cell densities.PD-L1 expression and CD68+macrophage density were positively correlated with IGF-1R expression in p16+HSPCC.In the p16+HPSCC group,the co-expression rate of IGF-1R/PD-L1 was significantly increased.Conclusion:IGF-1R expression could potentially serve as a better predictor of PD-1/PD-L1 inhibitor response rate in patients with HPSCC compared to p16 status.Combination therapy using IGF-1R inhibitors and PD-1/PD-L1 blockade may prove to be an effective treatment approach for patients with p16+HPSCC.
Wen-Jing Li;Xiao-Lin Xu;Li-Cheng Xu;Shun-Peng Wang;Yao-Yao Dong;Yi Wang;Xiao-Li Ren;Lei Ye;Peng-Yan Liu;Ming Liu;Lin-Li Tian
Department of Otorhinolaryngology,Head and Neck Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin,ChinaDepartment of Otorhinolaryngology,Head and Neck Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin,ChinaDepartment of Head and neck Surgery,Guangxi Medical University Cancer Hospital,Nanning,China Guangxi Cancer Institute,Nanning,ChinaDepartment of Otorhinolaryngology,Head and Neck Surgery,The Second Affiliated Hospital of Harbin Medical University,Chinese Ministry of Education,Harbin,ChinaDepartment of Otorhinolaryngology,Head and Neck Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin,ChinaDepartment of Otorhinolaryngology,Head and Neck Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin,ChinaDepartment of Otorhinolaryngology,Head and Neck Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin,ChinaDepartment of Otorhinolaryngology,Head and Neck Surgery,The Second Affiliated Hospital of Harbin Medical University,Chinese Ministry of Education,Harbin,ChinaDepartment of Otorhinolaryngology,Head and Neck Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin,ChinaDepartment of Otorhinolaryngology,Head and Neck Surgery,The Second Affiliated Hospital of Harbin Medical University,Chinese Ministry of Education,Harbin,ChinaDepartment of Otorhinolaryngology,Head and Neck Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin,China
医药卫生
hypopharyngeal neoplasmsIGF-1Rimmunotherapyp16PD-L1squamous cell carcinoma
《World Journal of Otorhinolaryngology-Head and Neck Surgery》 2026 (1)
P.112-123,12
the National Natural Science Foundation of China(Nos.82072987,82173209,82273332)。
评论